Board summary
Key figures
56,659
Registered population
65.3% aged 18–64
9.4%
Aged 65+
ICB 14.9% · England 17.9%
58.6%
Ethnic minority (non-White)
38.7% Asian · England 9.6%
86.1%
In IMD quintile 1
ICB 40.7% · England 21.0%
~46,073
Core20 residents (est.)
Resident basis; registered basis ~48,101 · see page 3
7,321
Hypertension register
+4.90% in 3 yrs · England +5.60%
758
SMI register
8% of Manchester (LAD)'s
1,238
COPD register
Reviews +11.32% in 3 yrs
Forecast to 2030
8,470
Hypertension patients, 2030
+1,149 on today
79.6%
QRISK ≥20% on statins, 2030
+2.16pp over 3 yrs
2.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Lipid therapy reach exceeds national and local benchmarks.
Lipid-lowering therapy for QRISK ≥ 20% reaches 75.1% (England 63.6%; Manchester (LAD) 70.5%), and 79.0% in CKD (England 70.3%).
Learning disability and COPD registers fell over three.
Three-year QOF prevalence fell 13.6% in learning disability (England +5.4%) and 4.0% in COPD (England +2.6%), which may reflect coding gaps to audit.
Screening and pre-school booster uptake lag national benchmarks.
Breast screening is 53.8% (England 69.9%, despite +23.0% three-year growth) and age-5 4-in-1 coverage is 80.7%, below the 95.0% target by 14.3 pp.
Population, age and ethnicity
Population, age and ethnicity
Census estimates show Asian / Asian British residents comprise 38.7% at PCN level, compared to 20.9% in Manchester (LAD), 13.6% in NHS Greater Manchester Integrated Care Board, and 9.6% in England. This Census measure reflects resident demographics rather than registered patient ethnicity; compare with GP records before assessing service reach.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 86.1% of the list, spanning 60.8 pp between practices
The PCN average IMD decile is 1.8 (Manchester (LAD) 3.0 decile; NHS Greater Manchester Integrated Care Board 4.5 decile; England 5.5 decile), with 86.1% of registered patients living in Core20 areas (Manchester (LAD) 59.8%; NHS Greater Manchester Integrated Care Board 40.7%; England 21.0%). Weighted practice share is 84.9% (a 1.17 percentage points discrepancy). Across practices, the Core20 share range is 60.8 pp. Hawthorn MC records 39.2%, while Gorton Medical Centre, Mount Road Surgery, and West Gorton Medical Practice each record 100.0%.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
758
SMI register
1.30% recorded prevalence
460
Learning disability register
0.79% recorded prevalence
10
Care homes, 282 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
Severe mental illness register (patients) is 758 at PCN level. No comparative benchmark was captured for this register count, so it provides baseline volume context only.
Severe mental illness: physical health checks
Severe mental illness QOF prevalence is 1.3% (758 patients). In the last 12 months, 82.4% had a blood pressure check (England 83.4%) and 81.2% had BMI recorded (England 82.1%). Other health check elements were not captured.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,321
Hypertension register
+4.90%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+6.48pp
BP control, under 80
≤140/90 · +3.98pp aged 80+
+1,149
More patients by 2030
Forecast 8,470 (13.86%)
Hypertension case-finding and control
Hypertension recorded QOF prevalence is 12.6% at PCN level, which is 2.1 percentage points above Manchester (LAD) (10.5%), but below NHS Greater Manchester Integrated Care Board (14.4%) by 1.8 percentage points and below England (15.2%) by 2.6 percentage points. Crude prevalence does not establish undiagnosed disease or case-finding quality; age-standardised comparisons would test whether differences reflect the younger population profile.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy is 75.1% at PCN level, exceeding England (63.6%) by 11.5 percentage points, NHS Greater Manchester Integrated Care Board (67.0%) by 8.1 percentage points, and Manchester (LAD) (70.5%) by 4.6 percentage points.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 103,313 | £2.00 | £1.94 | £1.86 | £206,626 |
| Cardiovascular (all), 2025 | 124,327 | £2.31 | £3.15 | £3.33 | £287,195 |
Cost per item for lipid-regulating drugs 2026 is £2.00 (England £1.86; NHS Greater Manchester Integrated Care Board £1.94; Manchester (LAD) £2.21). Across 103,313 items, annual spend is £206,626, which is £14,464 more than at England's unit cost. This unit-cost metric does not reflect treatment appropriateness or efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+12.66%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.85%
Asthma prevalence, PCN 3-yr % change
Asthma annual review coverage is 65.3% (England 65.7%), following a 3-year change of +12.7% (England +4.4%), leaving about 1,200 (1,174) of 3,384 patients unreviewed. Second-hand smoking recording for patients aged 6-19 years is 81.0% (England 78.8%). COPD reviews reached 73.2% (England 76.4%) after a 3-year change of +11.3% (England +2.8%), while COPD prevalence fell 4.0% (England +2.6%). Register changes could reflect coding differences to audit locally.
Cancer register and children's immunisation
Cancer register prevalence is 2.2% (1,307 patients; England 3.8%). In Q1 2025/26 childhood immunisation, coverage is below the 95.0% target: 6-in-1 at 12 months is 90.1%, MMR dose 1 at 24 months is 87.2%, and age-5 4-in-1 booster is 80.7% (14.3 pp below target). MMR dose 2 at age 5 is 85.6%, 5.3 pp below dose 1 (90.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage across NHS Greater Manchester ICB (6,491 of 11,679; 70.8% staged coverage) were diagnosed at stage 1 or 2, compared to 55.3% in England and 19.4 pp below the 75.0% ambition for 2028 (an ICB gap of about 2,270 cases annually; +3.1 pp since 2013). These system figures exclude unstaged cancers. Locally, PCN cervical screening is 61.7% (England 66.8%) and breast screening is 53.8% (England 69.9%). Lower primary care screening uptake could delay detection across pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For Jul 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the cancer 62-day referral to treatment standard (12.2 pp below the 85.0% standard) and 80.1% on the 28-day faster diagnosis standard (exceeding the 75.0% standard). On 62-day waits, Stockport NHS Foundation Trust reached 74.7% and Tameside and Glossop Integrated Care NHS Foundation Trust reached 76.8% (ICB 75.7%; England 71.2%). On the 28-day standard, Stockport NHS Foundation Trust was 83.2% and Tameside and Glossop Integrated Care NHS Foundation Trust was 82.5% (ICB 79.5%; England 79.3%). These hospital figures reflect wider provider pressures rather than PCN performance.
| Pathways within standard (%) | Manchester | Stockport | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 83.21 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 97.39 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 74.67 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Stockport | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 11.68 | 1.41 | 0.00 | 21.40 |
| CT | 14.66 | 2.93 | 0.18 | 9.92 |
| Echocardiography | 4.91 | 17.46 | 0.00 | 28.48 |
| Colonoscopy | 4.51 | 5.53 | 1.51 | 30.83 |
| Gastroscopy | 29.35 | 5.31 | 5.45 | 29.02 |
| All 15 DM01 tests | 8.98 | 14.08 | 0.80 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In provisional community services data for Jun 2026, 43.3% of community contacts among Manchester borough residents were with adults aged 65 and over (42,015 of 96,995 total contacts). This activity captures borough residents rather than PCN-registered patients, reflecting substantial older-age community health service demand across the local authority area.
Practice variation and patient experience
Vaccination and immunisation achievement varies by 84.4 pp across PCN practices
In 2025/26, clinical QOF achievement reached 100.0% at Mount Road Surgery. However, vaccination and immunisation domain achievement varied by 84.4 pp, from 15.6% at Gorton Medical Centre to 100.0% at Levenshulme Medical Practice, against 55.2% for England. High clinical domain achievement can coexist with wide variation in points awarded for immunisation.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Ashcroft Surgery | 114 | 87.8 | 60.6% | 69.7% | 91.1% |
| West Point | 102 | 63.1 | 70.7% | 82.9% | 83.0% |
| West Gorton | 90 | 100.0 | 47.6% | 75.5% | 78.2% |
| Levenshulme | 98 | 89.1 | 52.2% | 80.1% | 77.7% |
| Mount Road Surgery | 115 | 100.0 | 66.8% | 70.1% | 72.1% |
| Gorton | 92 | 100.0 | 55.1% | 65.9% | 70.3% |
| Hawthorn MC | 87 | 39.2 | 54.9% | 79.2% | 68.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten of 25 tracked measures trail England, led by learning disability falling 13.6%
Ten of 25 tracked measures trail England's three-year change. The widest relative lags are in learning disability prevalence, which fell 13.6% (England +5.4%), and heart failure reviews, which rose 1.4% (England +8.7%). Diabetes with cardiovascular disease statin therapy fell 2.8% (England +1.0%). Key clinical reviews improved: asthma reviews rose 12.7% (England +4.4%), COPD reviews rose 11.3% (England +2.8%), and severe mental illness blood pressure checks improved 9.6 pp (England +4.4 pp). Slower register growth could reflect local diagnostic coding practices rather than lower need, which clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
COPD register
Diabetes statin (CVD)
Asthma register
Breast screening (53-70)
COPD reviews
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 10 (282 beds) | n/a | Schools (catchment) | 76 | n/a |
| Children's centres | 5 | 34 | Places of worship | 50 | 289 |
| Libraries | 4 | 16 | Homelessness support (VCS) | 1 | 1 |
| Primary schools (LA maintained) | 11 | 68 | Primary academies | 7 | 50 |
| Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Standardised asthma annual review recall
Asthma review coverage is 65.3% (0.4 pp below England at 65.7% and 1.7 pp below Manchester (LAD) at 67.0%, despite +12.7% 3-year growth), leaving about 1,200 (1,174) of 3,384 asthma patients unreviewed. For discussion: run a single-template asthma review recall with after-school or holiday slots and inhaler checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Dementia case-finding and coding review
Recorded dementia QOF prevalence is 0.3% (170 patients vs 0.4% Manchester (LAD) and 0.8% England), giving an unadjusted benchmark scenario range of +55 to +273 patients. For discussion: search practice records for cognitive concern codes or dementia medicines without a register code. Moderate effort to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Differentiated Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Audit full SMI checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Preschool booster recall catchup (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Standardised asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Dementia case-finding and coding review (p12) | Dementia register · Dementia: QOF prevalence · Aged 65+ | 66.7% diagnosis ambition · 95% care plan 2027 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
